FDA
Stories
-
FDA releases draft guidance on electronic IDE submission template
Comments on the draft guidance are due by December 28, 2026. The guidance targets sponsors filing IDE applications with the Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research.
-
FDA releases draft guidance on U.S.-origin statements for seafood labeling
The notice was published on October 27, 2026. It will provide examples of labeling statements that the FDA would consider truthful and not misleading once finalized.
-
FDA determines PEPCID RPD famotidine tablets not withdrawn for safety or effectiveness
The agency decided that the 20 mg and 40 mg orally disintegrating tablets were not removed from sale. This determination will allow FDA to approve abbreviated new drug applications for these products if all other legal and regulatory requirements are met.
-
FDA actions, week of October 26, 2026: 2 approvals, 1 rule, 6 notices
The FDA published 9 actions in the week of October 26 to November 1, 2026: 2 approval announcements, 1 final rule in the Federal Register and 6 notices in the Federal Register.
-
FDA issues priority review voucher for ISEMBYLD (apitegromab-mstn)
The FDA announced the issuance of a priority review voucher to the sponsor of ISEMBYLD (apitegromab-mstn), approved September 11, 2026. The voucher is awarded because the product meets the criteria for rare pediatric disease applications under the FD&C Act.
-
FDA releases draft chapter on chemical hazard control for human food
The FDA announced the availability of a new draft chapter, Chapter 12: Control of Chemical Hazards, as part of its multichapter draft guidance on Hazard Analysis and Risk-Based Preventive Controls for Human Food. The guidance is not final and is not yet in effect.
-
FDA proposes action levels for cadmium in food for babies and young children
The FDA announced a draft guidance titled "Action Levels for Cadmium in Processed Food Intended for Babies and Young Children" that will establish action levels for cadmium in certain processed foods intended for babies and young children less than 2 years old. The draft guidance is intended to set achievable action levels that will help further reduce cadmium in the food supply.
-
FDA grants traditional approval for pembrolizumab and Keytruda QLEX for TMB-H solid tumors
On October 16, 2026 the FDA granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmh (Keytruda QLEX) for patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors defined as ≥13 mutations/megabase. In the KEYNOTE-158 study, 220 patients with TMB ≥13 mut/Mb had an objective response rate of 36% (95% CI: 30, 43) and 58% achieved a duration of response of at least 12 months.
-
Five of 10 October FDA approvals were new uses for cancer drugs the FDA had approved before
Five of the 10 FDA approvals dated October 1 to 20, 2026 added a use to a cancer drug the agency had approved before. One, dostarlimab in rectal cancer, is an accelerated approval with a confirmatory trial requirement projected to finish by July 31, 2030.
-
FDA approves once-weekly generic hormone therapy patch for women
The FDA approved the first generic of Climara Pro, a transdermal estradiol and levonorgestrel system (0.045 mg per day/0.015 mg) applied once a week for women with an intact uterus. The generic is therapeutically equivalent to Climara Pro and the most common adverse reactions are application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache and flu syndrome (≥5 %).
-
FDA approves first-of-its-kind chronic hepatitis B treatment
The FDA approved Hibsago (bepirovirsen) injection for adults without cirrhosis who have been on antiviral therapy for at least six months and have HBsAg levels of 3,000 IU/mL or less. The approval includes the Roche Elecsys HBsAg II quant II RxDx assay as a companion diagnostic.
-
FDA issues final guidance on prescription drug apps and software
The FDA released final guidance on October 20, 2026 that clarifies when app content is subject to FDA submission requirements and when it should be mentioned on a drug's official label. The guidance identifies two categories of companion software-apps connected to a medical device and standalone apps-and sets conditions for labeling and what companies should submit to the agency.